NovaBay Pharmaceuticals Business Summary

NovaBay Pharmaceuticals, Inc. (NBY) is a specialty biopharmaceutical company that generates revenue through the development and commercialization of non-antibiotic anti-infective products, primarily leveraging its proprietary Aganocide® technology and pure hypochlorous acid (HOCl) formulations. The company’s primary business segments are Eye Care and Wound Care, with its flagship product, Avenova® Antimicrobial Lid and Lash Solution, accounting for nearly 90% of total sales. Revenue is driven by a multi-channel model encompassing direct-to-consumer (DTC) online sales via Amazon and Avenova.com, professional prescriptions dispensed by optometrists, and a growing "Subscribe & Save" recurring revenue stream which represents approximately 25% of online transactions. NovaBay competes directly with specialty firms such as Sonoma Pharmaceuticals, Assertio Holdings, and Cumberland Pharmaceuticals, positioning itself as a niche leader in the HOCl-based ocular hygiene market following the strategic divestiture of its DERMAdoctor skincare brand to focus on high-margin eyecare assets. Founded in 2000 by Dr. Ron Najafi, the company’s early scientific pedigree was established by a founding team that included chemistry Nobel laureate Herbert C. Brown, Purdue Professor Dale Margerum, and Dr. Lu Wang. As of February 2026, the leadership team is led by Michael Kazley, who serves as Chief Executive Officer and Chairman of the Board following a significant 2025 management overhaul and capital infusion. Kazley, previously the Managing Member of R01 Fund LP, is supported by Chief Financial Officer Tommy Law, who rose through the company’s financial ranks since 2019, and Justin M. Hall, the long-standing General Counsel and VP of Business Development. The company’s governance and capital structure are heavily influenced by R01 Fund LP and Framework Ventures IV L.P., which collectively hold a controlling interest of approximately 45%, with a board of directors featuring industry veterans such as Paul E. Freiman, Swan Sit, and Dr. Yenyou Zheng.